8-K: Repligen Completes BioLife Solutions Acquisition

Repligen Corporation has successfully acquired BioLife Solutions, Inc., integrating its cell processing tools and services to expand its presence in the cell therapy market.

Summary

• Repligen Corporation has completed its acquisition of BioLife Solutions, Inc. through a two-step merger process, with the second merger effective on October 6, 2026.
• BioLife stockholders received 0.1442 shares of Repligen common stock and $11.25 in cash per share of BioLife common stock.
• Options, restricted stock units, and restricted stock awards for BioLife were accelerated and settled in shares of BioLife common stock, which then converted into the merger consideration.
• BioLife has ceased to exist as a separate legal entity and will be delisted from The Nasdaq Capital Market.
• Repligen will file financial statements and pro forma financial information in an amendment to this report within 71 days if required.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, marking the successful completion of a strategic acquisition that is expected to enhance Repligen's market position and revenue streams.

Positives

• Completion of a strategic acquisition expected to expand Repligen's presence in the rapidly growing cell therapy market.
• Addition of BioLife's high-margin consumables business with attractive recurring revenue.
• Enhanced ability to support customers across critical stages of the cell therapy workflow.
• BioLife's biopreservation media portfolio, including CryoStor, supports 18 commercially approved therapies and numerous cell-based therapy trials.
• Combined commercial team will leverage Repligen's global reach, including Asia Pacific.
• BioLife's trusted customer relationships will benefit Repligen.

Negatives

• BioLife Solutions, Inc. will be delisted from The Nasdaq Capital Market.
• Potential for integration challenges as two companies merge.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated.
• Risks discussed from time to time in Repligen's filings with the Securities and Exchange Commission could impact the realization of expected benefits.

Future Outlook

Repligen intends to provide additional detail regarding the transaction's expected impact on its 2026 financial outlook during the upcoming third quarter 2026 earnings call.

Management Comments

• "We are excited to welcome BioLife team members to Repligen," said Olivier Loeillot, President and Chief Executive Officer of Repligen.
• "BioLife's highly-differentiated portfolio of products expands our presence in the rapidly growing cell therapy market, adding a deeply embedded, high-margin consumables business with attractive recurring revenue."
• "Together, we are better positioned to support customers across critical stages of the cell therapy workflow and help advance the development and commercialization of next-generation therapies."
• "Over the past several months, our teams have worked closely together to develop a thoughtful integration plan, and we are even more excited about the strategic rationale of bringing our organizations together and the value we will create for patients, customers, and shareholders."

Industry Context

StockSavvy.ai notes that this acquisition aligns with the broader trend of consolidation in the life sciences sector, particularly within the rapidly expanding cell and gene therapy market, as companies seek to build comprehensive platforms and secure recurring revenue streams.

Stakeholder Impact

• Shareholders of BioLife have received cash and Repligen stock as consideration for their shares.
• Shareholders of Repligen will benefit from the expanded market presence and potential for increased revenue and profitability.
• Customers of both companies will have access to a more comprehensive suite of bioprocessing solutions.
• Employees of BioLife are now part of Repligen, with integration plans in development.

Next Steps

• Repligen intends to file financial statements and pro forma financial information in an amendment to this Current Report on Form 8-K no later than 71 calendar days after the filing date, if required.
• BioLife intends to file a Certification and Notice of Termination of Registration on Form 15 with the SEC to deregister its common stock and suspend reporting obligations.

Key Dates

Recommendation

The acquisition is a significant strategic move that is expected to be accretive, but the full financial impact and integration success will become clearer over time. A 'hold' recommendation allows for observation of post-acquisition performance and market reaction.

Keywords

acquisition, merger, cell therapy, bioprocessing, biopreservation media, consumables, recurring revenue, life sciences